Regulation of cytoskeleton organization by sphingosine in a mouse cell model of progressive ovarian cancer

Biomolecules

Volumn 3, Issue 3, 2013, Pages 386-407

  Creekmore, Amy L ^a   Lynn Heffron, C ^a   Brayfield, Bradley P ^a   Roberts, Paul C ^a   Schmelz, Eva M ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Cytoskeleton; Focal adhesions; MLCK; Ovarian cancer; Sphingosine

Indexed keywords

ALPHA ACTININ; BETA TUBULIN; F ACTIN; MYOSIN LIGHT CHAIN KINASE; SPHINGOSINE; VINCULIN;

ANIMAL CELL; ARTICLE; CELL INVASION; CONTROLLED STUDY; CYTOSKELETON; DOWN REGULATION; FOCAL ADHESION; IMMUNOFLUORESCENCE TEST; MICROFILAMENT; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 85016388566     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom3030386     Document Type: Article

References (65)

1. Howlader, N.; Noone, A.M.; Krapho, M.; Neyman, N.; Aminou, R.; Waldron, W.; Altekruse, S.F.; Kosary, C.L.; Ruhl, J.; Tatalovich, Z.; et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute: Bethesda, MD, USA, 2011; Available online: http://seer.cancer.gov/csr/1975_2008/ (accessed on July 2, 2013).
2. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics. CA Cancer J. Clin. 2010, 60, 277-300.
3. Barkan, D.; Kleinman, H.; Simmons, J.L.; Asmussen, H.; Kamaraju, A.K.; Hoenorhoff, M.J.; Liu, Z.Y.; Costes, S.V.; Cho, E.H.; Lockett, S.; et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 2008, 68, 6241-6250.
4. Pawlak, G.; Helfman, D.M. Cytoskeletal changes in cell transformation and tumorigenesis. Curr. Opin. Genet. Dev. 2001, 11, 41-47.
5. Provenzano, P.P.; Keely, P.J. Mechanical signaling through the cytoskeleton regulates cell proliferation by coordinated focal adhesion and Rho GTPase signaling. J. Cell Sci. 2011, 124, 1195-1205.
6. Ayollo, D.V.; Zhitnyak, I.Y.; Vasiliev, J.M.; Gloushankova, N.A. Rearrangements of the actin cytoskeleton and E-cadherin-based adherens junctions caused by neoplasic transformation change cell-cell interactions. PLoS One 2009, 4, e8027.
7. Lee, J.M.; Dedhar, S.; Kalluri, R.; Thompson, E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 2006, 172, 973-981.
8. Roberts, P.C.; Mottillo, E.P.; Baxa, A.C.; Heng, H.H.; Doyon-Reale, N.; Gregoire, L.; Lancaster, W.D.; Rabah, R.; Schmelz, E.M. Sequential molecular and cellular events during neoplastic progression: a mouse syngeneic ovarian cancer model. Neoplasia 2005, 7, 944-956.
9. Creekmore, A.L.; Silkworth, W.T.; Cimini, D.; Jensen, R.V.; Roberts, P.C.; Schmelz, E.M. Changes in gene expression and cellular architecture in an ovarian cancer progression model. PLoS One 2011, 6, e17676.
10. Anderson, A.S.; Roberts, P.C.; Frisard, M.I.; McMillan, R.P.; Brown, T.J.; Lawless, M.H.; Hulver, M.W.; Schmelz, E.M. Metabolic Changes During Ovarian Cancer Progression as Targets for SphingosineTreatment. Exp. Cell Res. 2013, 319, 1431-1442.
11. Ketene, A.N.; Schmelz, E.M.; Roberts, P.C.; Agah, M. The effects of cancer progression on the viscoelasticity of ovarian cell cytoskeleton structures. Nanomedicine 2012, 8, 93-102.
12. Ketene, A.N.; Roberts, P.C.; Shea, A.A.; Schmelz, E.M.; Agah, M. Actin filaments play a primary role for structural integrity and viscoelastic response in cells. Integrative Biology 2012, 4, 540-549.
13. Salmanzadeh, A.; Kittur, H.; Sano, M.B.; Roberts, P.C.; Schmelz, E.M.; Davalos, R.V. Dielectrophoretic differentiation of mouse ovarian surface epithelial cells, macrophages, and fibroblasts using contactless dielectrophoresis. Biomicrofluidics 2012, 6, 24104-24113.
14. Salmanzadeh, A.; Sano, M.B.; Gallo-Villanueva, R.C.; Roberts, P.C.; Schmelz, E.M.; Davalos, R.V. Investigating dielectric properties of different stages of syngeneic murine ovarian cancer cells. Biomicrofluidics 2013, 7, epublished online, DOI 10.1063/1.4788921.
15. Gangoiti, P.; Camacho, L.; Arana, L.; Ouro, A.; Granado, M.H.; Brizuela, L.; Casas, J.; Fabrias, G.; Abad, J.L.; Delgado, A.; Gomez-Munoz, A. Control of metabolism and signaling of simple bioactive sphingolipids: Implications in disease. Prog. Lipid Res. 2010, 49, 316-334.
16. Gault, C.R.; Obeid, L.M.; Hannun, Y.A. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv. Exp. Med. Biol. 2010, 688, 1-23.
17. Ryland, L.K.; Fox, T.E.; Liu, X.; Loughran, T.P.; Kester, M. Dysregulation of sphingolipid metabolism in cancer. Cancer Biol. Ther. 2011, 11, 138-149.
18. Dillehay, D.L.; Webb, S.K.; Schmelz, E.M.; Merrill, A.H., Jr. Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J. Nutr. 1994, 124, 615-620.
19. Schmelz, E.M.; Dillehay, D.L.; Webb, S.K.; Reiter, A.; Adams, J.; Merrill, A.H., Jr. Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas vs. adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res. 1996, 56, 4936-4941.
20. Schmelz, E.M.; Sullards, M.C.; Dillehay, D.L.; Merrill, A.H., Jr. Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1, 2-dimethylhydrazine-treated CF1 mice. J. Nutr. 2000, 130, 522-527.
21. Schmelz, E.M.; Roberts, P.C.; Kustin, E.M.; Lemonnier, L.A.; Sullards, M.C.; Dillehay, D.L.; Merrill, A.H., Jr. Modulation of intracellular beta-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res. 2001, 61, 6723-6729.
22. Lemonnier, L.A.; Dillehay, D.L.; Vespremi, M.J.; Abrams, J.; Brody, E.; Schmelz, E.M. Sphingomyelin in the suppression of colon tumors: Prevention vs. intervention. Arch. Biochem. Biophys. 2003, 419, 129-138.
23. Mazzei, J.C.; Zhou, H.; Brayfield, B.P.; Hontecillas, R.; Bassaganya-Riera, J.; Schmelz, E.M. Suppression of intestinal inflammation and inflammation-driven colon cancer in mice by dietary sphingomyelin: importance of peroxisome proliferator-activated receptor gamma expression. J. Nutr. Biochem. 2011, 22, 1160-1171.
24. Schmelz, E.M.; Crall, K.J.; Larocque, R.; Dillehay, D.L.; Merrill, A.H., Jr. Uptake and metabolism of sphingolipids in isolated intestinal loops of mice. J. Nutr. 1994, 124, 702-712.
25. Ohlsson, L.; Hertervig, E.; Jonsson, B.A.; Duan, R.D.; Nyberg, L.; Svernlov, R.; Nilsson, A. Sphingolipids in human ileostomy content after meals containing milk sphingomyelin. Am. J. Clin. Nutr. 2010, 91, 672-678.
26. Silins, I.; Nordstrand, M.; Hogberg, J.; Stenius, U. Sphingolipids suppress preneoplastic rat hepatocytes in vitro and in vivo. Carcinogenesis 2003, 24, 1077-1083.
27. Simon, K.W.; Tait, L.; Miller, F.; Cao, C.; Davy, K.P.; Leroith, T.; Schmelz, E.M. Suppression of breast xenograft growth and progression in nude mice: implications for the use of orally administered sphingolipids as chemopreventive agents against breast cancer. Food Funct. 2010, 1, 90-98.
28. Lim, K.G.; Sun, C.; Bittman, R.; Pyne, N.J.; Pyne, S. (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell Signal. 2011, 23, 1590-1595.
29. Donati, C.; Bruni, P. Sphingosine 1-phosphate regulates cytoskeleton dynamics: implications in its biological response. Biochim. Biophys. Acta 2006, 1758, 2037-2048.
30. Zeidan, Y.H.; Jenkins, R.W.; Hannun, Y.A. Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J. Cell. Biol. 2008, 181, 335-350.
31. Feldhaus, M.J.; Weyrich, A.S.; Zimmerman, G.A.; McIntyre, T.M. Ceramide generation in situ alters leukocyte cytoskeletal organization and beta 2-integrin function and causes complete degranulation. J. Biol. Chem. 2002, 277, 4285-4293.
32. Zheng, W.; Kollmeyer, J.; Symolon, H.; Momin, A.; Munter, E.; Wang, E.; Kelly, S., Allegood, J.C.; Liu, Y.; Peng, Q.; Ramaraju, H.; Sullards, M.C.; Cabot, M.; Merrill, A.H., Jr. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim. Biophys. Acta 2006, 1758, 1864-1884.
33. Liotta, D.C.; Bushnev, A.S.; Baillie, M.T.; Holt, J.J.; Menaldino, D.S.; Merrill, A.H. An efficient asymmetric synthesis of Enigmols (1-deoxy-5-hydroxysphingoid bases), an important class of bioactive lipid modulators. Arkivoc 2010, viii, 263-277.
34. Formigli, L.; Meacci, E.; Sassoli, C.; Chellini, F.; Giannini, R.; Quercioli, F.; Tiribilli, B.; Squecco, R.; Bruni, P.; Francini, F.; Zecchi-Orlandini, S. Sphingosine 1-phosphate induces cytoskeletal reorganization in C2C12 myoblasts: physiological relevance for stress fibres in the modulation of ion current through stretch-activated channels. J. Cell Sci. 2005, 118, 1161-1171.
35. Serrels, B.; Serrels, A.; Brunton, V.G.; Holt, M.; McLean, G.W.; Gray, C.H.; Jones, G.E.; Frame, M.C. Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex. Nat. Cell Biol. 2007, 9, 1046-1056.
36. Bai, C.Y.; Ohsugi, M.; Abe, Y.; Yamamoto, T. ZRP-1 controls Rho GTPase-mediated actin reorganization by localizing at cell-matrix and cell-cell adhesions. J. Cell Sci. 2007, 120, 2828-2837.
37. Tan, J.L.; Ravid, S.; Spudich, J.A. Control of nonmuscle myosins by phosphorylation. Annu. Rev. Biochem. 1992, 61, 721-759.
38. Jefferson, A.B.; Schulman, H. Sphingosine inhibits calmodulin-dependent enzymes. J. Biol. Chem. 1988, 263, 15241-15244.
39. Hanna, A.N.; Berthiaume, L.G.; Kikuchi, Y.; Begg, D.; Bourgoin, S.; Brindley, D.N. Tumor necrosis factor-alpha induces stress fiber formation through ceramide production: role of sphingosine kinase. Mol. Biol. Cell 2001, 12, 3618-3630.
40. Fillet, M.; Cren-Olive, C.; Renert, A.F.; Piette, J.; Vandermoere, F.; Rolando, C.; Merville, M.P. Differential expression of proteins in response to ceramide-mediated stress signal in colon cancer cells by 2-D gel electrophoresis and MALDI-TOF-MS. J. Proteome Res. 2005, 4, 870-880.
41. Singleton, P.A.; Dudek, S.M.; Chiang, E.T.; Garcia, J.G. Regulation of sphingosine 1-phosphate induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. FASEB J. 2005, 19, 1646-1656.
42. Wang, F.; Nobes, C.D.; Hall, A.; Spiegel, S. Sphingosine 1-phosphate stimulates rho-mediated tyrosine phosphorylation of focal adhesion kinase and paxillin in Swiss 3T3 fibroblasts. Biochem. J. 1997, 324, 481-488.
43. Strub, G.M.; Maceyka, M.; Hait, N.C.; Milstien, S.; Spiegel, S. Extracellular and intracellular actions of sphingosine-1-phosphate. Adv. Exp. Med. Biol. 2010, 688, 141-155.
44. Wang, D.; Zhao, Z.; Caperell-Grant, A.; Yang, G.; Mok, S.C.; Liu, J.; Bigsby, R.M.; Xu, Y. S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol. Cancer Ther. 2008, 7, 1993-2002.
45. Hong, G.; Baudhuin, L.M.; Xu, Y. Sphingosine-1-phosphate modulates growth and adhesion of ovarian cancer cells. FEBS Lett. 1999, 460, 513-518.
46. Canals, D.; Jenkins, R.W.; Roddy, P.; Hernandez-Corbacho, M.J.; Obeid, L.M.; Hannun, Y.A. Differential effects of ceramide and sphingosine 1-phosphate on ERM phosphorylation: probing sphingolipid signaling at the outer plasma membrane. J. Biol. Chem. 2010, 285, 32476-32485.
47. Seufferlein, T.; Rozengurt, E. Sphingosine induces p125FAK and paxillin tyrosine phosphorylation, actin stress fiber formation, and focal contact assembly in Swiss 3T3 cells. J. Biol. Chem. 1994, 269, 27610-27617.
48. Hannun, Y.A.; Loomis, C.R.; Merrill, A.H., Jr.; Bell, R.M. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J. Biol. Chem. 1986, 261,12604-12609.
49. Symolon, H.; Bushnev, A.; Peng, Q.; Ramaraju, H.; Mays, S.G.; Allegood, J.C.; Pruett, S T.; Sullards, M.C.; Dillehay, D.L.; Liotta, D.C.; Merrill, A.H., Jr. Enigmol: a novel sphingolipid analogue with anticancer activity against cancer cell lines and in vivo models for intestinal and prostate cancer. Mol. Cancer Ther. 2011, 10, 648-657.
50. Tsai, M.A.; Waugh, R.E.; Keng, P.C. Passive mechanical behavior of human neutrophils: effects of colchicine and paclitaxel. Biophys. J. 1998, 74, 3282-3291.
51. Suresh, S. Biomechanics and biophysics of cancer cells. Acta Biomater 2007, 3, 413-438.
52. Rajfur, Z.; Roy, P.; Otey, C.; Romer, L.; Jacobson, K. Dissecting the link between stress fibres and focal adhesions by CALI with EGFP fusion proteins. Nat. Cell Biol. 2002, 4, 286-293.
53. Salmanzadeh, A.; Elvington, E.S.; Roberts, P.C.; Schmelz, E.M.; Davalos, R.V. Sphingolipid metabolites modulate dielectric characteristics of cells in a mouse ovarian cancer progression model. Integr. Biol. 2013, 5, 843-852.
54. Ilic, D.; Furuta, Y.; Kanazawa, S.; Takeda, N.; Sobue, K.; Nakatsuji, N.; Nomura, S.; Fujimoto, J.; Okada, M.; Yamamoto, T. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995, 377, 539-544.
55. Grabel, L.B.; Hong, T. Migration of F9 parietal endoderm cells is regulated by the ERK pathway. J. Cell. Biochem. 2006, 97, 1339-1349.
56. Sjoblom, B.; Salmazo, A.; Djinovic-Carugo, K. Alpha-actinin structure and regulation. Cell. Mol. Life Sci. 2008, 65, 2688-26701.
57. Sood, A.K.; Armaiz-Pena, G.N.; Halder, J.; Nick, A.M.; Stone, R.L.; Hu, W.; Carroll, A.R.; Spannuth, W.A.; Deavers, M.T.; Allen, J.K.; et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J. Clin. Invest. 2010, 120, 1515-1523.
58. Schlaepfer, D.D.; Mitra, S.K.; Ilic, D. Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim. Biophys. Acta 2004, 1692, 77-102.
59. Schaller, M.D. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J. Cell. Sci. 2010, 123, 1007-1013.
60. Cui, W.J.; Liu, Y.; Zhou, X.L.; Wang, F.Z.; Zhang, X.D.; Ye, L.H. Myosin light chain kinase is responsible for high proliferative ability of breast cancer cells via anti-apoptosis involving p38 pathway. Acta Pharmacol. Sin. 2010, 31, 725-732.
61. Gutjahr, M.C.; Rossy, J.; Niggli, V. Role of Rho, Rac, and Rho-kinase in phosphorylation of myosin light chain, development of polarity, and spontaneous migration of Walker 256 carcinosarcoma cells. Exp. Cell Res. 2005, 308, 422-438.
62. Fazal, F.; Gu, L.; Ihnatovych, I.; Han, Y.; Hu, W.; Antic, N.; Carreira, F.; Blomquist, J.F.; Hope, T.J.; Ucker, D.S.; de Lanerolle, P. Inhibiting myosin light chain kinase induces apoptosis in vitro and in vivo. Mol. Cell Bio. 2005, 25, 6259-6266.
63. Schmelz, E.M.; Bushnev, A.S.; Dillehay, D.L.; Liotta, D.C.; Merrill, A.H., Jr. Suppression of aberrant colonic crypt foci by synthetic sphingomyelins with saturated or unsaturated sphingoid base backbones. Nutr. Cancer 1997, 28, 81-85.
64. Schmelz, E.M.; Dombrink-Kurtzman, M.A.; Roberts, P.C.; Kozutsumi, Y.; Kawasaki, T.; Merrill, A.H., Jr. Induction of apoptosis by fumonisin B1 in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases. Toxicol. Appl. Pharmacol. 1998, 148, 252-260.
65. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods 2001, 25, 402-408.